A Phase 3 Trial of Difelikefalin in Hemodialysis Patients with Pruritus

2019356 citationsJournal Article

Authors

Steven Fishbane · Donald & Barbara Zucker School of Medicine at Hofstra/Northwell

Catherine Munera · Cara Therapeutics (United States)

Warren Wen · Cara Therapeutics (United States)

Frédérique Menzaghi · Cara Therapeutics (United States)

Abstract

Patients treated with difelikefalin had a significant reduction in itch intensity and improved itch-related quality of life as compared with those who received placebo. (Funded by Cara Therapeutics; KALM-1 ClinicalTrials.gov number, NCT03422653.).

Topics & Keywords

Dermatology and Skin Diseases Neuropeptides and Animal Physiology Asthma and respiratory diseases

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: New England Journal of Medicine

Volume 382, Issue 3, pp. 222-232

DOI: 10.1056/nejmoa1912770

Field-Weighted Citation Impact: 28.20